Nunzia Pharmaceutical Corporation
Nunzia Pharmaceutical Company operates as a pharmaceutical and nutraceutical company. The company owns the right to manufacture, market, and distribute Nunzia, a nutraceutical that treats autism, fragile X, ADHD, PTSD, and other disorders. It offers its products through wholesalers, as well as through its website nunziapharma.com. The company was formerly known as Arizona Gold and Onyx Mining Com… Read more
Nunzia Pharmaceutical Corporation (NUNZ) - Total Assets
Latest total assets as of September 2022: $35.37K USD
Based on the latest financial reports, Nunzia Pharmaceutical Corporation (NUNZ) holds total assets worth $35.37K USD as of September 2022.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Nunzia Pharmaceutical Corporation - Total Assets Trend (2004–2021)
This chart illustrates how Nunzia Pharmaceutical Corporation’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Nunzia Pharmaceutical Corporation - Asset Composition Analysis
Current Asset Composition (December 2021)
Nunzia Pharmaceutical Corporation's total assets of $35.37K consist of 2.6% current assets and 97.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 2.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2004–2021)
This chart illustrates how Nunzia Pharmaceutical Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nunzia Pharmaceutical Corporation's current assets represent 2.6% of total assets in 2021, a decrease from 94.9% in 2004.
- Cash Position: Cash and equivalents constituted 2.6% of total assets in 2021, up from 0.0% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2004.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Nunzia Pharmaceutical Corporation Competitors by Total Assets
Key competitors of Nunzia Pharmaceutical Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Nunzia Pharmaceutical Corporation - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Nunzia Pharmaceutical Corporation generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Nunzia Pharmaceutical Corporation is currently not profitable relative to its asset base.
Nunzia Pharmaceutical Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.16 | 0.05 | 0.05 |
| Quick Ratio | 0.16 | 0.05 | 0.05 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-191.32K | $ -93.21K | $ -2.46 Million |
Nunzia Pharmaceutical Corporation - Advanced Valuation Insights
This section examines the relationship between Nunzia Pharmaceutical Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 8.47 |
| Asset Growth Rate (YoY) | 0.0% |
| Total Assets | $5.13K |
| Market Capitalization | $43.45K USD |
Valuation Analysis
Premium Asset Valuation: The market values Nunzia Pharmaceutical Corporation's assets at a significant premium ( 8.47x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: Nunzia Pharmaceutical Corporation's assets decreased by 0.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Nunzia Pharmaceutical Corporation (2004–2021)
The table below shows the annual total assets of Nunzia Pharmaceutical Corporation from 2004 to 2021.
| Year | Total Assets | Change |
|---|---|---|
| 2021-12-31 | $5.13K | -- |
| 2020-12-31 | $0.00 | -- |
| 2019-12-31 | $0.00 | -- |
| 2018-12-31 | $0.00 | -- |
| 2017-12-31 | $6.00K | -100.00% |
| 2010-12-31 | $1.48 Billion | +24636078.92% |
| 2008-12-31 | $6.00K | 0.00% |
| 2007-12-31 | $6.00K | 0.00% |
| 2006-12-31 | $6.00K | 0.00% |
| 2005-12-31 | $6.00K | -95.59% |
| 2004-12-31 | $136.00K | -- |